Tempus xT CDx represents a sophisticated approach to genomic profiling aimed at solid tumor malignancies, classified through DNA sequencing from both tumor and matched normal samples. This 648-gene panel spans a broad spectrum of genetic alterations, including INDELs and MSIs, and is strategically positioned to guide treatment protocols through detailed molecular diagnostics. As an essential instrument in personalized medicine, Tempus xT CDx not only supports targeted therapy identification but also enhances the selection process for applicable clinical trials by providing profound insights into a tumor's genetic landscape.
